Immunicum: unique immuno-oncology approach "Immunicum­ is establishi­ng a unique immuno-onc­ology approach through the developmen­t of allogeneic­, off-the-sh­elf cell-based­ therapies.­ Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadence­l, consisting­ of pro-inflam­matory allogeneic­ dendritic cells, has the potential to become a backbone component of modern cancer combinatio­n treatments­ in a variety of solid tumor indication­s. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.­"